China's Alzheimer’s Drug Approval Raises Hopes and Skepticism

Chinese company Shanghai Green Valley Pharmaceuticals received conditional approval to treat Alzheimer’s disease in China for its Oligomannate (GV-971). The news was met by hope, since it would break a long drought of approved therapies for Alzheimer’s, but questions as well—it sounds a little too good to be true.